The manufacturing process for Strangvac is proceeding according to plan
The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, finalized the production of the drug substances on a commercial scale in compliance with GMP (Good Manufacturing Practice). “We are very pleased to announce that we have now manufactured the drug substances for several million doses of Strangvac, the new vaccine against equine strangles" – says Andreas Andersson, CEO Intervacc AB “An important preparatory step has now been completed for the final completion of validation batches needed for submission of a registration